Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific for Blastic Plasmacytoid Dendritic Cell Neoplasm

Narittee Sukswai, Phyu P. Aung, C. Cameron Yin, Shaoying Li, Wei Wang, Sa A. Wang, Victor Ortega, Kirill Lyapichev, Priyadharsini Nagarajan, Rasha Alfattal, Evgeniya Angelova, Zhenya Tang, Sanam Loghavi, Rashmi Kanagal-Shamanna, Roberto N. Miranda, Naveen Pemmaraju, Kapil Bhalla, Marina Konopleva, L. Jeffrey Medeiros, Joseph D. Khoury

Research output: Contribution to journalArticlepeer-review


The diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been based on the expression status of multiple markers, including CD123. TCF4 was discovered recently to be an obligatory master regulator of plasmacytoid dendritic cells. We postulated that a tissue-based assay designed to detect dual CD123 and TCF4 expression would provide a highly reliable and practical marker for BPDCN in biopsy material. We designed, optimized, and validated a dual-color TCF4/CD123 immunohistochemistry stain for use in formalin-fixed paraffin-embedded tissue sections. The performance characteristics of the TCF4/CD123 stain were evaluated in 48 confirmed BPDCN cases. TCF4/CD123 coexpression was detected reproducibly in plasmacytoid dendritic cells. In BPDCN, the TCF4/CD123 stain showed coexpression in all (48/48; 100%) cases analyzed. Cases with concurrent samples from different anatomic sites showed comparable staining characteristics. In contrast, of 464 non-BPDCN cases comprising a wide range of hematolymphoid neoplasms and cutaneous lesions that might enter in the differential diagnosis of BPDCN, we identified dual expression of TCF4 and CD123 in only 1 case of B-lymphoblastic leukemia/lymphoma. On the basis of these findings, the TCF4/CD123 dual-color immunohistochemical stain had an analytic sensitivity of 100% and a specificity of 99.8%. Receiver operator characteristic analysis demonstrated an area under the curve of 1.000 (95% confidence interval: 0.999-1.000). In summary, the dual-color TCF4/CD123 immunohistochemistry stain provides a robust standalone and cost-effective assay for the diagnosis of BPDCN.

Original languageEnglish (US)
Pages (from-to)1429-1437
Number of pages9
JournalAmerican Journal of Surgical Pathology
Issue number10
StatePublished - Oct 1 2019
Externally publishedYes


  • CD123
  • TCF4
  • blastic plasmacytoid dendritic cell neoplasm
  • bone marrow
  • immunohistochemistry
  • skin

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine


Dive into the research topics of 'Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific for Blastic Plasmacytoid Dendritic Cell Neoplasm'. Together they form a unique fingerprint.

Cite this